Fidelity Select Biotechnology Pt: (MF: FBIOX)
NAV
$145.63
NAV Day Change
-2.27 (-1.54%)
May 16 06:05 PM ET
General Information As Of 04/30/13
| %Yield | 0.00 |
| %SEC Yield | NA |
| %YTD Return (as of 04/30/13) | 27.37 |
| Objective* | Equity - Sector Health |
| Peer* | HL MG |
Portfolio Statistics
| %Unrealized Gain YTD | 24.12 |
| Net Assets (Mil $) 04/30/2013 | 4,896.77 |
| %Turnover 04/30/2013 | 42.00 |
Fees
| %Max Sales Load | NA |
| %Min Sales Load | NA |
| %Max Deferred Load | NA |
Expenses
| %Max 12b-1 Fee | 0.00 |
| %Max Management Fee | 0.56 |
| Redemption Fee | 0.75 |
| Expense Ratio | 0.81 |
Allocation
| Large Growth | 51.27 |
| Large Value | 0.00 |
| Small Growth | 0.00 |
| Small Value | 0.00 |
| Foreign Stock | 0.00 |
| Emerging Market | 0.00 |
| Precious Metal | 0.00 |
| Intermediate Bond | 0.00 |
| Foreign Bond | 0.00 |
| High Yield Bond | 0.00 |
Portfolio Information
Composition
| As of 02/28/2013 | %of Net Assets |
| Stock | 99.31 |
| Cash | 7.92 |
| Bonds | 0.00 |
| Preferred | 0.24 |
| Convertibles | 0.17 |
| Foreign Stock | 1.49 |
| Foreign Bonds | 0.00 |
| Hedge | 0.00 |
| Other | -7.65 |
Sector / Country Weightings
| As of 04/30/2013 | % of Portfolio |
|---|---|
| Health | 61.36 |
| Services | 23.37 |
| Other | 7.49 |
| Industrial Cyclical | 6.88 |
| Technology | 0.64 |
| Retail Trade | 0.24 |
| Energy | 0.02 |
Portfolio Holdings
| Top Equity Holdings (As of 11/30/2012) | % of Portfolio | Value (Mil$) |
|---|---|---|
| GILEAD SCIENCES INC | 13.77 | 369.23 |
| AMGEN INC | 12.81 | 343.34 |
| BIOGEN IDEC INC | 7.39 | 197.98 |
| REGENERON PHARMACEUTICALS | 5.79 | 155.20 |
| CELGENE CORP | 4.66 | 124.88 |
| ONYX PHARMACEUTICALS INC | 3.61 | 96.70 |
| MEDIVATION INC | 3.49 | 93.55 |
| VERTEX PHARMACEUTICALS IN | 2.73 | 73.29 |
| BIOMARIN PHARMACEUTICAL | 2.46 | 66.01 |
Contact Information
| Family | Fidelity |
| Addrerss | 82 Devonshire St Boston, MA 02109 |
| Phone | 800 544-6666 |
Zacks Premium Research
Zacks Mutual Fund Rank: 1 - Strong Buy 
| #1 |
Fund Description
Incepted in December 1985 and managed by the Fidelity Group, the objective of this fund is to seek capital appreciation. It normally invests at least 80% of assets in common stocks of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund offers dividends and capital gains in the month of April and December.
Stock Holding % of Net Assets
| As Of | 02/28/2013 |
| Total Issues | 127 |
| Avg. P/E | 40.53 |
| Avg. P/Book | 5.64 |
| Avg. EPS Growth | 15.35 |
| Avg. Market Value (Mil $) | 28,428 |
Risk
| 3 Year | 5 Year | 10 Year | |
|---|---|---|---|
| Beta | 1.04 | 0.74 | 0.78 |
| Alpha | 13.26 | 15.70 | 7.13 |
| R Squared | 0.66 | 0.45 | 0.38 |
| Std. Dev. | 19.21 | 20.75 | 18.63 |
| Sharpe | 1.53 | 1.03 | 3.00 |
Shareholder Information
| Manager | Rajiv Kaul |
| Since | 10/05 |
| Manager Rating | 6.30 |
| Inception Date | 12/16/1985 |
| Shareholders | NA |
| Dividends Paid | S |
| Minimum Initial Investment | $2,500 |
| Minimum Subsequent Investment | $0 |
| IRA Minimum | $2500 |
| IRA Available | Y | Check Writing | N | Phone Invest | Y |
| Phone Exchange | Y | Phone Redeem | Y | Auto Invest | Y |
| Wire Redeem | Y | Wire Fee | Y | Wire Transfer | Y |
Zacks Commentary for FBIOX
Zacks Blog: Top 5 Zacks #1 Ranked Fidelity Mutual Funds
Apr 23, 2013
Zacks Blog: Top 5 Best Performing Healthcare Mutual Funds Year to Date
Jan 24, 2013
Zacks Blog: Top 5 Zacks #1 Ranked Healthcare Mutual Funds
Jan 02, 2013
Zacks Blog: Top 5 Best Performing Healthcare Mutual Funds Year to Date
Nov 28, 2012
Zacks Blog: Top 5 Zacks #1 Ranked Healthcare Mutual Funds
Nov 23, 2012
